Prolia Related Published Studies
Well-designed clinical trials related to Prolia (Denosumab)
Clinical Trials Express: fracture risk reduction with denosumab in Japanese
postmenopausal women and men with osteoporosis: denosumab fracture intervention
randomized placebo controlled trial (DIRECT). [2014]
Delaying skeletal-related events in a randomized phase 3 study of denosumab
versus zoledronic acid in patients with advanced cancer: an analysis of data from
patients with solid tumors. [2014]
Superiority of denosumab to zoledronic acid for prevention of skeletal-related
events: a combined analysis of 3 pivotal, randomised, phase 3 trials. [2012]
Responder analysis of the effects of denosumab on bone mineral density in men
receiving androgen deprivation therapy for prostate cancer. [2012]
Dose-response study of denosumab on bone mineral density and bone turnover
markers in Japanese postmenopausal women with osteoporosis. [2012]
Infections in postmenopausal women with osteoporosis treated with denosumab or
placebo: coincidence or causal association? [2012]
Denosumab for the prevention of osteoporotic fractures in post-menopausal women: a NICE single technology appraisal. [2011.11.01]
Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association? [2011.09.03]
Effects of denosumab on fracture and bone mineral density by level of kidney function. [2011.08]
Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. [2011.06]
Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. [2011.04]
Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. [2011.03.20]
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. [2011.03.05]
Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. [2011.03]
A randomized, double-blind, placebo-controlled, single-dose study to evaluate the
safety, tolerability, pharmacokinetics and pharmacodynamics of denosumab
administered subcutaneously to postmenopausal Japanese women. [2011]
Randomized, double-blind study of denosumab versus zoledronic acid in the
treatment of bone metastases in patients with advanced cancer (excluding breast
and prostate cancer) or multiple myeloma. [2011]
Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. [2010.12.10]
Clinical use of denosumab for the treatment for postmenopausal osteoporosis. [2010.12]
Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. [2010.10]
Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density. [2010.07]
Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates. [2010.05]
Denosumab-mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid arthritis patients. [2010.04]
Denosumab prevents metacarpal shaft cortical bone loss in patients with erosive rheumatoid arthritis. [2010.04]
Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure. [2010.03]
Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. [2010.01]
Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. [2010]
Denosumab prevents metacarpal shaft cortical bone loss in patients with erosive
rheumatoid arthritis. [2010]
Effects of denosumab on bone mineral density and bone turnover in patients with
rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates. [2010]
Effects of denosumab on bone mineral density and bone turnover in postmenopausal
women transitioning from alendronate therapy. [2010]
Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. [2009.12]
Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study. [2009.11]
Efficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis: a systematic review and a meta-analysis. [2009.10]
Denosumab in men receiving androgen-deprivation therapy for prostate cancer. [2009.08.20]
Denosumab for prevention of fractures in postmenopausal women with osteoporosis. [2009.08.20]
Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial. [2009.08]
Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. [2009.04.01]
Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. [2009.01]
Is twice-yearly denosumab beneficial in postmenopausal women with osteopenia but no history of fracture? [2008.12]
Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. [2008.10.20]
Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. [2008.10.15]
Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial. [2008.08]
Integrated cellular bone homeostasis model for denosumab pharmacodynamics in multiple myeloma patients. [2008.08]
Effects of denosumab on the geometry of the proximal femur in postmenopausal women in comparison with alendronate. [2008.07]
Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. [2008.06]
Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. [2008.05]
Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. [2007.12]
Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. [2007.10.01]
Well-designed clinical trials possibly related to Prolia (Denosumab)
Ranking antireabsorptive agents to prevent vertebral fractures in postmenopausal
osteoporosis by mixed treatment comparison meta-analysis. [2013]
Adjuvant therapy with bone-targeted agents. [2011.09]
Estimating minimally important differences for the worst pain rating of the Brief Pain Inventory-Short Form. [2011.03]
Estimating minimally important differences for the worst pain rating of the Brief
Pain Inventory-Short Form. [2011]
Antifracture efficacy of currently available therapies for postmenopausal
osteoporosis. [2011]
Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass. [2010.05]
Preference and satisfaction with a 6-month subcutaneous injection versus a weekly
tablet for treatment of low bone mass. [2010]
Update on the treatment of post-menopausal osteoporosis. [2008]
Other research related to Prolia (Denosumab)
Influence of patient perceptions and preferences for osteoporosis medication on
adherence behavior in the Denosumab Adherence Preference Satisfaction study. [2014]
Time course of bone mineral density changes with denosumab compared with other
drugs in postmenopausal osteoporosis: a dose-response-based meta-analysis. [2014]
Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a
meta-analysis of seven randomized controlled trials. [2014]
Denosumab in patients with cancer and skeletal metastases: a systematic review
and meta-analysis. [2013]
Effects of denosumab on cortical and trabecular microarchitecture: evidences from
clinical studies. [2013]
A new antiresorptive approach to the treatment of fragility fractures: long-term
efficacy and safety of denosumab. [2013]
Effects of pioglitazone on bone in postmenopausal women with impaired fasting
glucose or impaired glucose tolerance: a randomized, double-blind,
placebo-controlled study. [2013]
Denosumab compared with ibandronate in postmenopausal women previously treated
with bisphosphonate therapy: a randomized open-label trial. [2013]
Incidence and risk of denosumab-related hypocalcemia in cancer patients: a
systematic review and pooled analysis of randomized controlled studies. [2013]
Denosumab treatment of prostate cancer with bone metastases and increased urine
N-telopeptide levels after therapy with intravenous bisphosphonates: results of a
randomized phase II trial. [2013]
One-year long-term safety extension study of ospemifene for the treatment of
vulvar and vaginal atrophy in postmenopausal women with a uterus. [2013]
Denosumab in patients with cancer and skeletal metastases: a systematic review
and meta-analysis. [2013]
Efficacy and safety of denosumab versus zoledronic acid in patients with bone
metastases: a systematic review and meta-analysis. [2013]
Interpreting results from oncology clinical trials: a comparison of denosumab to
zoledronic acid for the prevention of skeletal-related events in cancer patients. [2012]
Denosumab reduces the risk of osteoporotic fractures in postmenopausal women,
particularly in those with moderate to high fracture risk as assessed with FRAX. [2012]
Denosumab for the prevention of skeletal-related events in patients with bone
metastasis from solid tumor. [2012]
Comparison of clinical efficacy and safety between denosumab and alendronate in
postmenopausal women with osteoporosis: a meta-analysis. [2012]
Denosumab and the current status of bone-modifying drugs in breast cancer. [2012]
Relationship between bone mineral density changes with denosumab treatment and
risk reduction for vertebral and nonvertebral fractures. [2012]
Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures. [2011.11.16]
Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. [2011.11.15]
Denosumab for the reduction of bone loss in postmenopausal osteoporosis: a review. [2011.11]
A randomized, double-blind, placebo-controlled, single-dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of denosumab administered subcutaneously to postmenopausal Japanese women. [2011.11]
Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis. [2011.10.04]
Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases. [2011.10]
Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. [2011.09.17]
Dose-response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis. [2011.09.17]
Denosumab: benefits of RANK ligand inhibition in cancer patients. [2011.09]
[Denosumab as the potent therapeutic agent against Paget's disease of bone]. [2011.08]
Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. [2011.05]
Economic evaluation of denosumab compared with zoledronic acid in
hormone-refractory prostate cancer patients with bone metastases. [2011]
Effects of denosumab on fracture and bone mineral density by level of kidney
function. [2011]
Denosumab for the treatment of osteoporosis. [2010.12]
Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. [2010.09.13]
Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate. [2010.09.09]
Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. [2010.08]
Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women. [2010.07]
Treatment of osteoporosis with denosumab. [2010.06]
Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. [2010.03]
Denosumab--an emerging treatment for postmenopausal osteoporosis. [2010.03]
Comparison of the Effect of Denosumab and Alendronate on Bone Mineral Density and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial. [2009.12.14]
[From orthoclone to denosumab, the fast growing market of monoclonal antibodies] [2009.12]
Denosumab: the era of targeted therapies in bone metastatic diseases. [2009.11]
Denosumab. [2009.05]
Other possibly related research studies
Osteonecrosis of the jaws induced by anti-RANK ligand therapy. [2010.04]
Safety considerations for use of bone-targeted agents in patients with cancer. [2010.06]
|
